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Protein engineering as a tool for crystallography 
Stephen R Price and Kiyoshi Nagai 
MRC Laboratory of Molecular Biology, Cambridge, UK 
The generation of large quantities of protein by overexpression technology has 
enabled structural studies of many important molecules that are found in only 
minute quantities in the cell. An increasing number of structures of proteins 
overexpressed in non-native systems have been solved. Crystallographers 
now have an extremely powerful tool, namely protein engineering, for the 
generation of native and derivative crystals that diffract to high resolution. The 
mutation of residues or generation of compact domains through truncation 
has resulted in crystals with enhanced diffraction properties. Heavy atom 
derivative crystals isomorphous to the native protein may also be engineered 
either by introducing cysteines or by removing cysteines whose reaction with 
heavy-atom compounds results in poor crystals. 
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Introduction Use of protein engineering to improve crystals 
The first crystals grown of a newly studied protein 
are rarely of difhaction quality. If there is a secret to 
the preparation of crystals of biological macromolecules 
for high-resolution structural studies, it lies in the 
identification and exploitation of parameters critical to 
formation of the crystals. One parameter is ignored reg- 
ularly - it has been used to improve the quality of native 
crystals and to facilitate the generation of derivative 
crystals- this parameter is the protein sequence itself, 
modification of which can be accomplished by protein 
engineering. The preparation of crystals represents an 
assay; one can change the crystallization conditions and 
monitor the effect on crystal quality. With this assay and 
a biochemical assay for functionality, mutations may be 
made in the protein that may improve the crystals whilst 
retaining the function. This is rather akin to attempting 
to crystallize the same protein horn different native 
sources, an oft used approach in the days before protein 
engineering. 
Proteins ofien have a modular structure consisting of 
several distinct domains (independent folding units) that 
are tethered by flexible linkers. In the majority of 
cases, each domain may be treated as independent from 
each other for the purposes of a structural study. An 
understanding of the domain structure is often important 
in deciding upon the protein construct to crystallize. 
Clearly, a study of the actions of the protein as a 
whole requires a study of the protein as a whole; thus, 
although structures of a DNA-binding domain and an 
activation domain from a transcription &actor help to 
explain DNA binding and activation, respectively, they 
may not always tell how DNA binding affects activation. 
Yet, information on the two separate functions is still of 
considerable interest. 
The two major obstacles to success in macromolecular 
crystallography are obtaining crystals that difhact well 
and the generation of their isomorphous heavy-atom 
derivatives. The use of overexpression systems not only 
allows us to obtain large quantities of proteins that 
normally exist in minute quantities in the cell, but also 
provides an opportunity to specifically modif) protein 
molecules to overcome these obstacles. In this review, 
we deal neither with the overexpression of proteins 
nor with the initial crystallization trials, as these topics 
have been covered elsewhere [1,2]; instead, we focus on 
strategies either to obtain crystals with good difhaction 
properties or to improve existing crystals through protein 
engineering. 
Gross flexibility in a protein may be thought of as 
generating heterogeneity in structure. Removal of a 
flexible linker region between two domains in the study 
of each separately can aid in crystallization by mini- 
mizing any interfering effects resulting fi-om this micro- 
heterogeneity. Protein engineering allows the production 
of these domains in isolation, without the need for 
proteolysis of the intact protein, which often results in 
heterogeneity itself. Identification of domain boundaries 
may be possible through comparisons of aligned protein 
sequences from different species. It is of vital importance, 
however, to have experimental evidence for the domain 
boundary from limited proteolysis of the wild-type 
protein using proteases of differing specificity. The 
precise cleavage site of each protease may be identified 
by amino-terminal sequencing and mass spectrometry of 
the cleaved fragments. Mass spectrometry also allows 
the identification of any microheterogeneity in the 
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sample through partial processing of the amino-terminal 
methionine, post-translational modification or limited 
proteolysis, which can occur during purification of 
the sample. These types of microheterogeneity may be 
removed at the outset through, for example, engineering 
of an amino-terminal sequence that is processed fully 
[3,4**] or synthesis of a more compact domain resistant 
to proteases [5-71. As a caveat to this section, it 
is worth mentioning the HIV-l reverse transcriptase, 
where p66 and proteolysed p51 (which has lost the 
RNase H domain) form the active heterodimer. The 
equivalent parts in p66 and ~51 assume substantially 
different tertiary structures [8], and any of the possible 
homodimers are inactive, which illustrates the need for 
a functional assay. 
In addition to protein crystallography, heterogeneity 
in preparations of RNA for RNA crystallography 
or RNA-protein crystallography may be removed 
by engineering. The use of &acting hammerhead 
ribozymes to generate RNA with defined termini by 
in vitro transcription has been described [9]. Previous 
methodologies for the preparation of RNA for structural 
studies employed run-off transcription that utilized 
phage RNA polymerases. These methods limit the 
sequences that may be made, with the polymerase also 
generating heterogeneity at the 3’ terminus as it runs 
off. By utilizing two [is-acting ribozymes co-transcribed 
with the desired RNA sequence in between, the 
types of sequence possible are limited only by the 
specificity of the ribozymes (a considerable improvement 
on the limitations imposed by the polymerase), with 
3’ heterogeneity removed because the 3’ terminus is 
generated by site-specific cleavage. 
Engineering of crystal contacts 
Crystal contacts are mediated by the interaction of 
surface residues and are dependent on the character 
of the interacting moities. When crystals are of poor 
quality, amino acid residues likely to be on the protein 
surface may be mutated to remove weak contacts or 
to introduce residues that may promote good surface 
interaction. A definitive selection of mutations is not 
possible in the absence of the three-dimensonal structure 
and knowledge of crystal contacts, but consideration of 
a few existing examples may be useful in designing such 
mutations. Brange et al. [lo] made several mutants of 
insulin to prevent hexamer formation, which they had 
observed in their crystals. The replacement of small 
hydrophobic groups with large hydrophobic groups 
was not effective in destabilizing the protein contacts 
and larger side chains were readily accommodated by 
slight re-arrangements of packing. Electrostatic repulsion 
of charged side chains was much more effective in 
preventing hexamer formation. In the absence of 
detailed structural knowledge, it is dangerous to mutate 
a hydrophobic amino acid to a charged amino acid 
because a hydrophobic residue may be internal, and its 
replacement with a charged residue is likely to disrupt 
the core structure. Charged amino acids are likely to 
be solvent exposed and their mutation to uncharged 
hydrophilic groups or hydrophobic groups may alter 
crystal packing. 
Some examples of how protein engineering has 
been used to improve crystals 
CroEL 
GroEL is a large protein assembly involved in the 
ATP-dependent folding of polypeptide chains. Seven 
identical subunits assemble into a torus with sevenfold 
rotational symmetry which, in turn, stacks back-to-back 
within the crystal [l l**]. The original native crystals 
did not diffract well; however, a double point mutant 
carrying the (functionally null) Argl3+Gly (three-letter 
amino acid code) and Alal26+Val mutations produced 
crystals with considerably better diffraction qualities. 
These mutations were introduced by polymerase error 
during PCR and make the multimeric protein assembly 
less stable, although still functional. It is believed that the 
mutant crystals diffracted better than the native crystals 
because they had a lower affinity for peptides which 
co-purifjr with the native protein. 
A complex of Ul A spliceosomal protein and its cognate 
RNA hairpin 
UlA protein is a component of the Ul small nu- 
clear ribonucleoprotein particle involved in pre-mRNA 
splicing. In an attempt to crystallize a complex of 
UlA protein and its cognate RNA hairpin, RNAs 
with various stem lengths and overhanging nucleotides 
were initially added to the native protein fragment 
[4**]. Cubic crystals, similar in morphology to those 
obtained using the protein on its own, diffkacting to 
only 7A resolution were obtained consistently. It was 
believed that crystal contacts within the protein-RNA 
crystal were the same as those within the crystals of 
the protein alone. If this assumption were true, then 
disruption of these contacts would likely result in a 
different crystal form, possibly with better d&action 
qualities. Protein dimers interact within the protein 
crystal through a hydrophobic surface; a Ghr39+Arg 
mutation was introduced into the protein in an attempt 
to disrupt this surface. During the PCR to introduce 
this mutation, an additional mutation, Tyr36+His, was 
also introduced in error. A combination of the double 
mutant protein and a 21-nucleotide RNA resulted 
in a hexagonal crystal form di&acting beyond 1.7 A 
resolution. These two mutations form crucial crystal 
contacts, His36 is packed against a nucleotide base at the 
end of the stem and also interacts with the overhanging 
base [12]. Proteins containing either mutation singly did 
not produce crystals. Structural knowledge of the protein 
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rable 1. Examples of protein structure determinations that have been facilitated by protein engineering. 
structure (source) Mutations* Comments* References 
<NA-binding domain 
>f LJlA protein 
Homo sapiens) 
Successful mutants included SerZV+Cys, 
Gln3V+Cys, Cln54+Cys, Clu61 -Kys, 
Ser71 -Kys and Cln85-Kys. Unsuccessful 
mutants included Thrb-Kys, Thrll -Kys, 
Ser63-+Cys and Asp7V+Cys 
The Cln85+Cys mutant without heavy atoms 
produced crystals larger than the wild type 
and was used as the ‘native’ dataset. All 
mutants were pre-reacted with heavy- 
atom compounds, with the exception of 
GlnBS-Kys 
[6,261 
RNA-binding domain 
3f Ul A protein 
:omplexed with a 
item-loop of RNA 
:H. sapiens) 
Gln3V+Arg, Tyr36+His and others. 
For a discussion, see [4**1 
Two surface mutations, Gln3V+Arg and 
Tyr36-Kys proved critical for 
crystallization. In addition, many mutations 
were made in order to generate a completely 
processed amino terminus 
140.. 121 
Ribosomal protein L6 
It?aci/lus 
srearorbermophilus) 
Vall24-Kys. (No natural cysteines 
are found in L6) 
This protein, purified from the native 
source, was crystallized in 1983, but no 
derivatives could be made. Overexpression 
allowed the engineering of the Vall24+Cys 
mutation. Vall24 was chosen because E. co/i 
L6 protein has a cysteine at this position. 
A selenomethionine derivative is also used. 
iI71 
Ribosomal protein LV 
lBaci/lus 
s~earothermophilus) 
Successful mutants included Asn27_tCys, 
Gk~100+Cys, Leu35+Met and Leul24+Met. 
Unsuccessful mutants were AsnZO+Cys, 
Gln33-+Cys, ThrrlO-Kys 
lys45+Cys and Glnl OS+Cys 
Crystals of L9 protein purified from 
B. stearothermophilus were first grown 
in 1979, but the structure proved insoluble. 
Protein engineering enabled solution of the 
structure. Of all the mutations, Asn27+Cys 
and GlulOO+Cys gave the best crystals, 
although crystals of the former mutants were in 
a different space group. Leu3S+Met and 
Leul24+MetLvere introduced in order 
to label with selenomethionine; their presence 
proved invaluable in chain tracing 
[I81 
Cutinase 
(Fusarium so/am) 
Ser4+Cys, SerVZ-Kys, 
Serl2O-Kys and Serl2V-Kys 
Each wine is mutated to cysteine in turn. 
Out of the 14 possible mutants, four crystallized 
isomorphously to the native enzyme, leading to 
useful derivatives. Interestingly, one of the 
mutations was to catalytically active serine 
[I91 
Tenascin, fibronectin 
type III domain 
(H. sapiens) 
Ubiquitin-conjugating 
enzyme E2 
(Arabidopsis haliana) 
Not applicable 
Cysll4-tSer 
A selenomethionine derivative was used 
Data were collected at four wavelengths 
around the selenium absorption edge 
Reaction of the two cysteines in the wild type 
with heavy-atom compounds resulted in derivatives 
non-isomorphous to the native crystals. This 
Cysll4+Ser mutation solved the problem; 
reaction of the remaining cysteines with heavy-atom 
compounds resulted in three useful derivatives 
[311 
[231 
Interferon-y 
(H. sapiens) 
Five carboxy-terminal residues 
deleted by protein engineering 
The carboxyl terminus was targeted because it 
was known to be protease sensitive. A compact 
domain was generated by the mutations 
[5,401 
‘Amino acids are given in the three-letter code. 
component was used to design one of the mutations, but 
in the absence of the structure of the cubic form, it is 
not possible to tell whether the hydrophobic surface is 
used to pack the complex in the cubic crystals of the 
native protein. 
protein, which comprises 288 amino acid residues, is 
required for 3’ processing and DNA strand transfer 
activities, but a fragment consisting of residues 50-212 
is capable of carrying out the integration reaction. 
Crystals of the native protein d&act poorly and Dyda 
et al. [13**] have undertaken a systematic approach to 
mutating hydrophobic residues. A single amino acid 
HIV integrase 
HIV integrase is an enzyme involved in the integration 
of viral DNA into the host genome. The intact 
substitution of Phel85+Lys results in a protein with 
improved solubility and native activity. The structure has 
been solved to 2.5A resolution. The mutated protein 
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assembles as dimers in solution, whereas the native 
protein forms more complex aggregates. The amino 
group of the mutated lysine residue is hydrogen bonded 
to the main-chain carbonyl group of Ala105 of the 
adjacent molecule within the dimer. It remains to be 
seen whether engineering of this sort will become 
commonplace for the generation of better native crystals 
with a view towards the solution of other structural 
problems in biology (see also [14]). 
Use of protein engineering in the generation of 
isomorphous heavy-atom derivatives 
Conventionally, heavy-atom derivatives are obtained 
by soaking crystals in a solution of a heavy-atom 
compound. Heavy-atom compounds covalently react 
with amino acid side chains (e.g. cysteine, methionine 
and histidine), form ionic bonds with charged groups, 
or become trapped in a binding pocket (for a review, 
see [15]). The properties of heavy-atom compounds 
and examples of their use can be found in Blundell and 
Johnson [16]. Searching for derivatives involves soaking 
different heavy-atom compounds into native crystals, 
with preliminary data collection and data processing. 
This process can be time-consuming and sometimes 
requires many precious crystals. Serious problems arise 
when reactive amino acids are located near crystal 
contacts. In these cases, attachment of heavy-atom 
compounds to these amino acids ofien causes cracking 
of crystals or results in non-isomorphous crystals. 
Sometimes proteins do not contain binding sites for 
heavy-atom compounds, thus making it difficult to 
prepare heavy-atom derivatives. Protein engineering has 
been used to introduce cysteine residues into the protein, 
ideally on the surface where they are accessible to 
solvent and unlikely to disrupt the core structure of 
the protein [6,12,17-191. When no cysteines are present 
in the wild-type protein, this technique represents a 
significant improvement on previous methods, which 
involved labelling less reactive groups. If soaking results 
in the cracking of crystals, some of the reactive residues 
can be mutated to unreactive amino acids [20-231. 
The use of protein mutagenesis for the preparation 
of heavy-atom derivatives was first achieved using T4 
lysozyme [24] and applied to solve the structure of fl 
resolvase [25]. Serine is similar to cysteine in size and 
a Ser+Cys mutation is unlikely to cause a structural 
change in the protein or to affect crystal packing. 
Although cysteine is structurally similar to serine, the 
heavy-atom bound form is not; thus, there is no reason 
a priori to favour a Ser+Cys mutation over all others. 
In addition, serine can be buried, so it may be better 
to choose residues more likely to be on the surface of 
the protein (e.g. a charged amino acid or glutamine), 
although at present, trial and error is probably the 
best strategy for success. By introducing a cysteine at 
what one hopes is a surface site, one runs the risk of 
creating unnatural disulphide linked protein dimers. This 
may be avoided either by reacting the cysteine mutant 
with the derivatizing compound before setting up 
crystallizations or through crystallizing in the presence 
of a reducing agent such as dithiothreitol. Pre-reaction 
guarantees 100% occupancy of the heavy-atom sites, 
whereas soaking makes use of crystal packing forces 
that more likely, but not necessarily, constrain the crystal 
to a structure that is isomorphous to the native protein 
(for a more complete discussion, see [26]). Table 1 shows 
examples of protein structures that have been facilitated 
in solution by protein engineering. 
Use of selenomethionine-containing proteins as 
heavy-atom derivatives 
Unlike the mutagenesis method discussed above, the use 
of selenomethionine does not require further modifica- 
tion of the protein sequence [17,27-371. Incorporating 
selenomethionine into proteins through overexpression 
in bacteria grown with seleno-L-methionine as the 
only source of methionine is, in principle, likely to 
yield derivative crystals isomorphous to the native. The 
chemistry of selenium is similar to that of sulphur (they 
are both in the same group of the periodic table). 
Furthermore, methionine is not likely to be involved in 
critical crystal contacts. The advantages of this method 
are that incorporation of the heavy atom should be close 
to complete (thus, simplifjring considerably the solution 
of the Patterson map), and that the identity and number 
of sites is known unambiguously, with each site acting 
as a landmark when tracing the electron density. Until 
recently, selenomethionine-labelled proteins had to be 
overexpressed in a strain of Escherichia coli auxotrophic 
for methionine biosynthesis. Yet, Bottomley et al. 
[38] have reported the almost complete incorporation 
of selenomethionine into vascular cellular adhesion 
molecule type 1 by utilizing a non-auxotrophic strain 
grown in the presence of seleno-I_-methionine as the 
sole source of methionine. Methionines have also been 
incorporated into a protein in order to label with 
selenomethionine [39]. In addition, the number of 
structures solved using only selenomethionine-derived 
phases is increasing steadily [31,34,36]. (As a precau- 
tionary note, readers should be aware that all heavy-atom 
containing compounds and selenomethionine are toxic 
and should be treated with great care.) 
Conclusions 
Protein engineering may be used to help in the 
improvement of crystals and in the generation of 
heavy-atom derivatives. When used to complement 
existing methods, its application can only increase the 
likelihood of success in macromolecular crystallization. 
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Indeed, in some cases, the use of protein engineering has 
been critical to the success&l completion of the project. 
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